Move over CRISPR: a new platform, TGEE, could soon...
Dec. 11, 2019
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
TargetGene Biotechnologies
Main focus: Gene editing for the treatment of genetic diseases and cancer
Company stage: Pre-clinical
Diseases: Cancer, immune disorders
Genome editing tool: TargetGene Genome-Editing Engine (TGEE)
Funding stage: Private
Location: Rehovot, HaMerkaz, Israel
Website: https://targetgenebio.com/
TargetGene Biotechnologies has developed a novel gene-editing platform called TargetGene Genome-Editing Engine (TGEE). Like conventional CRISPR systems, the technology uses RNA-guided nucleases for gene editing. However, the system uses two guide RNAs istead of one. In this way, the technology achieves highly efficient and specific editing of the target sequence. While the company yet has to disclose its lead programmes, it will mainly focus on cancer and immune disorders.
